Syndicated Research Studies

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period. According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 6...

Anti-Vascular Endothelial Growth Factor Therapeutics Industry Overview The global anti-vascular endothelial growth factor therapeutics market size was valued at USD 11.67 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 0.5% from 2021 to 2028. The anti-Vascular Endothelial Growth Factor (VEGF) therapeutics market growth can be attributed to an increase in the prevalence of ophthalmic diseases, such as macular edema, diabetic retinopathy, retinal vein occlusion, and Age-related Macular Degeneration (AMD), coupled with an increasing geriatric population that is exposed to the risk of developing the condition. According to the WHO, around 196 million people are affected by AMD globally, which includes over 10.4 million cases with moderate to severe vision impairment. In addition, product launches and research advancements are contributing to market growth. AMD is the leading cause of vision loss among the Canadian population; it affected around 1.4 mil...